178 related articles for article (PubMed ID: 29753123)
21. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study.
Heier JS; Boyer DS; Ciulla TA; Ferrone PJ; Jumper JM; Gentile RC; Kotlovker D; Chung CY; Kim RY;
Arch Ophthalmol; 2006 Nov; 124(11):1532-42. PubMed ID: 17101999
[TBL] [Abstract][Full Text] [Related]
22. [Functional and Morphological Microstructural Changes in SD-OCT in Long-Term Treatment for Neovascular AMD with Ranibizumab - Monotherapy Versus Combination Therapy with PDT].
Wand K; Tetz K; Fischinger IR; Lohmann CP; Maier MM; Feucht N
Klin Monbl Augenheilkd; 2017 Jun; 234(6):805-810. PubMed ID: 27454303
[No Abstract] [Full Text] [Related]
23. Ranibizumab monotherapy versus single-session verteporfin photodynamic therapy combined with as-needed ranibizumab treatment for the management of neovascular age-related macular degeneration.
Bashshur ZF; Schakal AR; El-Mollayess GM; Arafat S; Jaafar D; Salti HI
Retina; 2011 Apr; 31(4):636-44. PubMed ID: 21124254
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of the siRNA PF-04523655 versus ranibizumab for the treatment of neovascular age-related macular degeneration (MONET Study).
Nguyen QD; Schachar RA; Nduaka CI; Sperling M; Klamerus KJ; Chi-Burris K; Yan E; Paggiarino DA; Rosenblatt I; Aitchison R; Erlich SS;
Ophthalmology; 2012 Sep; 119(9):1867-73. PubMed ID: 22683252
[TBL] [Abstract][Full Text] [Related]
25. [Intravitreal ranibizumab in combination with verteporfin photodynamic therapy in neovascular macular degeneration].
Soucek P; Soucková I
Cesk Slov Oftalmol; 2008 Jul; 64(4):135-40. PubMed ID: 18780651
[TBL] [Abstract][Full Text] [Related]
26. INITIAL VERSUS DELAYED PHOTODYNAMIC THERAPY IN COMBINATION WITH RANIBIZUMAB FOR TREATMENT OF POLYPOIDAL CHOROIDAL VASCULOPATHY: The Fujisan Study.
Gomi F; Oshima Y; Mori R; Kano M; Saito M; Yamashita A; Iwata E; Maruko R;
Retina; 2015 Aug; 35(8):1569-76. PubMed ID: 25830698
[TBL] [Abstract][Full Text] [Related]
27. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): year 2 results.
Antoszyk AN; Tuomi L; Chung CY; Singh A;
Am J Ophthalmol; 2008 May; 145(5):862-74. PubMed ID: 18321465
[TBL] [Abstract][Full Text] [Related]
28. Intravitreal ranibizumab and bevacizumab in combination with full-fluence verteporfin therapy and dexamethasone for exudative age-related macular degeneration.
Forte R; Bonavolontà P; Benayoun Y; Adenis JP; Robert PY
Ophthalmic Res; 2011; 45(3):129-34. PubMed ID: 20847575
[TBL] [Abstract][Full Text] [Related]
29. A randomised prospective double-masked exploratory study comparing combination photodynamic treatment and intravitreal ranibizumab vs intravitreal ranibizumab monotherapy in the treatment of neovascular age-related macular degeneration.
Vallance JH; Johnson B; Majid MA; Banerjee S; Mandal K; Bailey CC
Eye (Lond); 2010 Oct; 24(10):1561-7. PubMed ID: 20577273
[TBL] [Abstract][Full Text] [Related]
30. Three-year visual outcomes of intravitreal ranibizumab with or without photodynamic therapy for polypoidal choroidal vasculopathy.
Sakai T; Okano K; Kohno H; Tsuneoka H
Acta Ophthalmol; 2016 Dec; 94(8):e765-e771. PubMed ID: 27237048
[TBL] [Abstract][Full Text] [Related]
31. Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration.
Busbee BG; Ho AC; Brown DM; Heier JS; Suñer IJ; Li Z; Rubio RG; Lai P;
Ophthalmology; 2013 May; 120(5):1046-56. PubMed ID: 23352196
[TBL] [Abstract][Full Text] [Related]
32. Two-year results of combined intravitreal ranibizumab and photodynamic therapy for retinal angiomatous proliferation.
Saito M; Iida T; Kano M; Itagaki K
Jpn J Ophthalmol; 2016 Jan; 60(1):42-50. PubMed ID: 26498642
[TBL] [Abstract][Full Text] [Related]
33. Combined therapy (intravitreal bevacizumab plus verteporfin photodynamic therapy) versus intravitreal bevacizumab monotherapy for choroidal neovascularization due to age-related macular degeneration: a 1-year follow-up study.
Saviano S; Leon PE; Mangogna A; Tognetto D
Digit J Ophthalmol; 2016; 22(2):46-53. PubMed ID: 27582675
[TBL] [Abstract][Full Text] [Related]
34. Combination therapy with intravitreal tissue plasminogen activator and ranibizumab for subfoveal type 2 choroidal neovascularization.
Kachi I; Yasukawa T; Kato A; Takase N; Morita H; Kubota A; Hirano Y; Uemura A; Ogura Y
Jpn J Ophthalmol; 2016 May; 60(3):179-86. PubMed ID: 26919844
[TBL] [Abstract][Full Text] [Related]
35. Reduced-fluence verteporfin photodynamic therapy plus ranibizumab for choroidal neovascularization in pathologic myopia.
Rinaldi M; Semeraro F; Chiosi F; Russo A; Romano MR; Savastano MC; dell'Omo R; Costagliola C
Graefes Arch Clin Exp Ophthalmol; 2017 Mar; 255(3):529-539. PubMed ID: 27680013
[TBL] [Abstract][Full Text] [Related]
36. Practicability confirmation by meta-analysis of intravitreal ranibizumab compared to photodynamic therapy to treat polypoidal choroidal vasculopathy.
Liu L; Ma J; Duan P; Liu Y; Yin ZQ
Mol Vis; 2015; 21():1130-41. PubMed ID: 26539025
[TBL] [Abstract][Full Text] [Related]
37. Intravitreal Bevacizumab Versus Ranibizumab for Treatment of Neovascular Age-Related Macular Degeneration: Findings from a Cochrane Systematic Review.
Solomon SD; Lindsley KB; Krzystolik MG; Vedula SS; Hawkins BS
Ophthalmology; 2016 Jan; 123(1):70-77.e1. PubMed ID: 26477843
[TBL] [Abstract][Full Text] [Related]
38. Ranibizumab treatment outcomes in phakic versus pseudophakic eyes: an individual patient data analysis of 2 phase 3 trials.
Weinberg DV; Shapiro H; Ehrlich JS
Ophthalmology; 2013 Jun; 120(6):1278-82. PubMed ID: 23453513
[TBL] [Abstract][Full Text] [Related]
39. Combination of bevacizumab and photodynamic therapy vs. bevacizumab monotherapy for the treatment of wet age-related macular degeneration: A meta-analysis of randomized controlled trials.
Wei Q; Liu J; Liu Q; Ren C; Cai W; Liang X; Wen J; Yu J
Exp Ther Med; 2018 Aug; 16(2):1187-1194. PubMed ID: 30116368
[TBL] [Abstract][Full Text] [Related]
40. Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results.
Kaiser PK; Brown DM; Zhang K; Hudson HL; Holz FG; Shapiro H; Schneider S; Acharya NR
Am J Ophthalmol; 2007 Dec; 144(6):850-857. PubMed ID: 17949673
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
